In this study, we analyzed the impact of a recombinant inhibitor of CD95L on the respective tri-lateral cross-talk using highly malignant pancreatic cancer cells as a model and in context of the standard chemotherapeutic agent, gemcitabine. This evidence concerns the gene FASLG and familial pancreatic carcinoma.